Table 2 Correlation of PDGFR A13 and B19 mutational status and clinical-pathological features

Gender

0.754

0.346

 · Female

24 (85.7)

4 (14.3)

10 (34.5)

19 (65.5)

 · Male

36 (80.0)

9 (20.0)

23 (46.9)

26 (53.1)

Age

0.127

0.653

 · ≤ 68-years old (median)

34 (89.5)

4 (10.5)

18 (45.0)

22 (55.0)

 · > 68-years old (median)

26 (74.3)

9 (25.7)

15 (39.5)

23 (60.5)

CEA (carcinoembryonic antigen)

1.000

0.813

 · Within normal range

39 (83.0)

8 (17.0)

21 (41.2)

30 (58.8)

 · ≥ ULN (5 ng/ml)

21 (80.8)

5 (19.2)

12 (44.4)

15 (55.6)

Primary tumour location

1.000

0.051

 · Colon

47 (82.5)

10 (17.5)

22 (36.1)

39 (63.9)

Rectum

13 (81.3)

3 (18.8)

11 (64.7)

6 (35.3)

Tumour histology

0.401

0.221

 · Conventional adenocarcinoma

52 (83.9)

10 (16.1)

30 (45.5)

36 (54.5)

 · Mucinous or colloid adenocarcinoma

8 (72.7)

3 (27.3)

3 (25.0)

9 (75.0)

TNM stage

0.196

0.170

 · I-II

23 (92.0)

2 (8.0)

8 (30.8)

18 (69.2)

 · III-IV

37 (78.7)

10 (21.3)

24 (47.1)

27 (52.9)

Tumour differentiation

0.053

0.586

 · Well differentiated

15 (100)

0 (0.0)

7 (36.8)

12 (63.3)

 · Moderately or poorly differentiated

37 (77.1)

11 (22.9)

23 (47.9)

25 (52.1)

Surgery of primary tumor

0.578

0.389

 · Yes

55 (80.9)

13 (19.1)

32 (43.8)

41 (56.2)

 · No

5 (100.0)

0 (0.0)

1 (20.0)

4 (80.0)

Surgery of metastasis

0.953

0.451

 · Yes

13 (86.7)

2 (13.3)

9 (50.0)

9 (50.0)

 · No

47 (81.0)

11 (19.0)

24 (40.0)

24 (40.0)

Adjuvant chemotherapy

0.295

0.986

 · Yes

28 (87.5)

4 (12.5)

14 (42.4)

19 (57.6)

 · No

32 (78.0)

9 (22.0)

19 (42.2)

26 (57.8)

Chemotherapy for advanced disease

0.683

0.929

 · Yes

36 (83.7)

7 (16.3)

18 (41.9)

25 (58.1)

 · No

24 (80.0)

6 (20.0)

15 (42.9)

20 (57.1)